First-line efgartigimod could soon be more than a hypothetical therapeutic option for patients with acetylcholine receptor antibody-positive
Efgartigimod Outperforms Standard IVIG in Averting Myasthenic Crisis

First-line efgartigimod could soon be more than a hypothetical therapeutic option for patients with acetylcholine receptor antibody-positive